Nordic Capital’s Nycomed in possible €8bn sale

The possible sale could be worth as much as €8bn. Nycomed is headquartered in Zurich but was established in Norway in 1874 and has previously been based in Oslo, Norway and Roskilde, Denmark. Negotiations are believed to be in the early stages and are not guaranteed to result in a deal.

Nordic Capital acquired Nycomed in 2005 from DLJ Merchant Banking, part of CSFB's Alternative Capital Division, and The Blackstone Group. The investor had previously owned the company between 1999 and 2002.

Nycomed is a pharmaceutical company that employs 12,500 associates worldwide and has affiliates in more than 70 countries. In 2010, the company generated total net turnover of €3.2bn, with an adjusted EBITDA of €851m.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Exits
• Nordic Capital
• Trade sale
• Switzerland
• Norway
• Denmark